7 research outputs found
Galaxies with a central minimum in stellar luminosity density
We used Hubble Space Telescope WFPC2 images to identify six early-type galaxies with surface brightness profiles that decrease inward over a limited range of radii near their centers. The inferred luminosity density profiles of these galaxies have local minima interior to their core break radii. NGC 3706 harbors a high surface brightness ring of starlight with radius â20 pc. Its central structure may be related to that in the double-nucleus galaxies M31 and NGC 4486B. NGC 4406 and NGC 6876 have nearly flat cores that, on close inspection, are centrally depressed. Colors for both galaxies imply that this is not due to dust absorption. The surface brightness distributions of both galaxies are consistent with stellar tori that are more diffuse than the sharply defined system in NGC 3706. The remaining three galaxies are the brightest cluster galaxies in A260, A347, and A3574. Color information is not available for these objects, but they strongly resemble NGC 4406 and NGC 6876 in their cores. The thin ring in NGC 3706 may have formed dissipatively. The five other galaxies resemble the endpoints of some simulations of the merging of two gas-free stellar systems, each harboring a massive nuclear black hole. In one version of this scenario, diffuse stellar tori are produced when stars initially bound to one black hole are tidally stripped away by the second black hole. Alternatively, some inward-decreasing surface brightness profiles may reflect the ejection of stars from a core during the hardening of the binary black hole created during the merger
Efeito da ordem dos exercĂcios no nĂșmero de repetiçÔes e na percepção subjetiva de esforço em homens treinados em força
Effect of Ceasing Creatine Supplementation while Maintaining Resistance Training in Older Men
Carla Task Force on Sarcopenia: Propositions for clinical trials
In the presence of an aging population, public health priorities need to evolve. As the populations gets older, the already existing pathologies have become commonplace with specific geriatric clinical syndromes like frailty, mobility disability, or cognitive impairment, among others. Sarcopenia is a good example for which geriatricians, neurologists, physiologists, nutritionists and epidemiologists need to find a consensual definition and diagnostic tool as well as guidelines for the management of clinical trials and possible treatments. The Carla Sarcopenia Task Force, which met in the south of France (Toulouse) for an expert consensus meeting called âLes Entretiens du Carlaâ, have addressed a series of existing issues to place Sarcopenia into a nosological context: a definition which should be a composite of a change in muscle mass and a change in strength/function depending on either a progressive and chronic wasting process or an acute onset of loss of muscle mass; a recommendation for DXA and the Short Physical Performance Battery as a clinical pragmatic approach of Sarcopenia; a differentiated approach for clinical studies according to prevention or treatment objectives and depending on the sub-groups and target populations; and finally, a summary of therapeutic strategies currently recommended. The aim of âLes Entretiens du Carlaâ, based on an expert meeting panel, was to address a series of unsolved issues in the field of Sarcopenia by combining the expert opinion with a revision of the existing literature on the topic. Through this report, the reader will appreciate the determination to find conclusions on the various issues and further studies to be developed to determine the best multidisciplinary approach needed
Sarcopenia: its assessment, etiology, pathogenesis, consequences and future
Sarcopenia is a loss of muscle protein mass and loss of muscle function. It occurs with increasing age, being a major component in the development of frailty. Current knowledge on its assessment, etiology, pathogenesis, consequences and future perspectives are reported in the present review. On-going and future clinical trials on sarcopenia may radically change our preventive and therapeutic approaches of mobility disability in older peopleY. Rolland, S. Czerwinski, G. Abellan Van Kan, J.E. Morley, M. Cesari, G. Onder, J. Woo, R. Baumgartner, F. Pillard, Y. Boirie, W.M.C. Chumlea, B. Vella